Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination

被引:3
作者
van den Biggelaar, Anita H. J. [1 ]
Richmond, Peter C. [2 ]
Fuery, Angela [2 ,5 ]
Anderson, Denise [1 ]
Opa, Christine [3 ]
Saleu, Gerard [3 ]
Lai, Mildred [3 ]
Francis, Jacinta P. [3 ]
Alpers, Michael P. [4 ]
Pomat, William S. [3 ]
Lehmann, Deborah [1 ]
机构
[1] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia
[2] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia
[3] Papua New Guinea Inst Med Res, Goroka, Eastern Highlan, Papua N Guinea
[4] Curtin Univ, Sch Hlth Sci, Int Hlth, Perth, WA, Australia
[5] Baylor Coll Med, Houston, TX 77030 USA
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会; 英国惠康基金;
关键词
RESPIRATORY-TRACT INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; IMMUNE-RESPONSE; HYPORESPONSIVENESS; IMMUNOGENICITY; DISEASE; PERSISTENCE; 7-VALENT; EFFICACY; BOOSTER;
D O I
10.1371/journal.pone.0185877
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Trial design In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 9 months of age. We here studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in these children at 3-5 years of age (n = 132), and in 121 community controls of a similar age with no prior pneumococcal vaccination. Methods Circulating IgG antibody titers to all PCV7 and PPV23-only serotypes 2, 5 and 7F were measured before and after challenge with 1/5 th of a normal PPV23 dose. Serotype-specific memory B-cells were enumerated at 10 months and 3-5 years of age for a subgroup of study children. Results Serotype-specific IgG antibody titers before and after challenge were similar for children who received PCV7/PPV23, PPV23 only, or no pneumococcal vaccines. Before challenge, at least 89% and 59% of children in all groups had serotype-specific titers similar to 0.35 mu g/ml and similar to 1.0 mu g/ml, respectively. Post-challenge antibody titers were higher or similar to pre-challenge titers for most children independent of pneumococcal vaccination history. The rise in antibody titers was significantly lower when pre-challenge titers were higher. Overall the relative number of serotype-specific memory B-cells remained the same or increased between 10 months and 3-5 years of age, and there were no differences in serotype-specific memory B-cell numbers at 3-5 years of age between the three groups. Conclusions Immunity induced by PCV7 and/or PPV23 immunization in infancy does not exceed that of naturally acquired immunity in 3-5-year-old children living in a highly endemic area. Also, there was no evidence that PPV23 immunization in the first year of life following PCV7 priming induces longer-term hypo-responsiveness.
引用
收藏
页数:18
相关论文
共 34 条
[1]  
Aho Celestine, 2016, Vaccine Rep, V6, P36, DOI 10.1016/j.vacrep.2016.08.002
[2]  
Carey VJ, 2012, GEE GEN ESTIMATION E, P181
[3]   Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells [J].
Clutterbuck, Elizabeth A. ;
Lazarus, Rajeka ;
Yu, Ly-Mee ;
Bowman, Jaclyn ;
Bateman, Elizabeth A. L. ;
Diggle, Linda ;
Angus, Brian ;
Peto, Tim E. ;
Beverley, Peter C. ;
Mant, David ;
Pollard, Andrew J. .
JOURNAL OF INFECTIOUS DISEASES, 2012, 205 (09) :1408-1416
[4]   SAFETY AND IMMUNOGENICITY OF A POLYVALENT ESCHERICHIA-COLI VACCINE IN HUMAN VOLUNTEERS [J].
CROSS, A ;
ARTENSTEIN, A ;
QUE, J ;
FREDEKING, T ;
FURER, E ;
SADOFF, JC ;
CRYZ, SJ .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (04) :834-840
[5]   Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial [J].
Cutts, FT ;
Zaman, SMA ;
Enwere, G ;
Jaffar, S ;
Levine, OS ;
Okoko, JB ;
Oluwalana, C ;
Vaughan, A ;
Obaro, SK ;
Leach, A ;
McAdam, KP ;
Biney, E ;
Saaka, M ;
Onwuchekwa, U ;
Yallop, F ;
Pierce, NF ;
Greenwood, BM ;
Adegbola, RA .
LANCET, 2005, 365 (9465) :1139-1146
[6]   Attenuated immune response to tetanus toxoid in young healthy men protected against tetanus [J].
Danilova, E ;
Shiryayev, A ;
Kristoffersen, EK ;
Sjursen, H .
VACCINE, 2005, 23 (42) :4980-4983
[7]   Short-term booster effect of diphtheria toxoid in initially long-term protected individuals [J].
Danilova, E ;
Shiryayev, A ;
Skogen, V ;
Sjursen, H .
VACCINE, 2005, 23 (12) :1446-1450
[8]   The Efficacy and Duration of Protection of Pneumococcal Conjugate Vaccines Against Nasopharyngeal Carriage A Meta-regression Model [J].
De Waroux, Olivier Le Polain ;
Flasche, Stefan ;
Prieto-Merino, David ;
Goldblatt, David ;
Edmunds, W. John .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (08) :858-864
[9]   Human Infant Memory B Cell and CD4+T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine [J].
Fuery, Angela ;
Richmond, Peter C. ;
Currie, Andrew J. .
PLOS ONE, 2015, 10 (07)
[10]   Reconsideration of the use of meningococcal polysaccharide vaccine [J].
Granoff, Dan M. ;
Pollard, Andrew J. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (08) :716-722